Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease

Bibliography

• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349(9064):1498-504
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532-55
   PubMed Web of Science ®Google Scholar
• Liu Y, Croft JB, Anderson LA, et al. The association of chronic obstructive pulmonary disease, disability, engagement in social activities, and mortality among US adults aged 70 years or older, 1994-2006. Int J Chron Obstruct Pulmon Dis 2014;9:75-83
   PubMed Web of Science ®Google Scholar
• Di Marco F, Milic-Emili J, Boveri B, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003;21(1):86-94
   PubMed Web of Science ®Google Scholar
• Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003;124(5):1743-8
   PubMed Web of Science ®Google Scholar
• Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008;134(2):255-62
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009;6(1):17-25
   PubMedGoogle Scholar
• Rodrigo GJ, Plaza V. Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review. Chest 2014;146(2):309-17
   PubMed Web of Science ®Google Scholar
• Kodgule R, Vaidya A, Salvi S. Newer therapies for chronic obstructive pulmona disease. J Assoc Physicians India 2012;60(Suppl):8-13
   PubMedGoogle Scholar
• Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 2009;331(2):740-51
   PubMed Web of Science ®Google Scholar
• Roffel AF, Elzinga CR, Zaagsma J. Muscarinic M3 receptors mediate contraction of human central and peripheral airway smooth muscle. Pulm Pharmacol 1990;3(1):47-51
   PubMedGoogle Scholar
• Maltais F, Milot J. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Ther Adv Respir Dis 2012;6(6):345-61
   PubMed Web of Science ®Google Scholar
• Lasseter KC, Aubets J, Chuecos F, Gil EG. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. J Clin Pharmacol 2011;51(6):923-32
   PubMed Web of Science ®Google Scholar
• Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012;40(4):830-6
   PubMed Web of Science ®Google Scholar
• Kerwin EM, D’Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012;9(2):90-101
   PubMedGoogle Scholar
• Sentellas S, Ramos I, Alberti J, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010;39(5):283-90
   PubMed Web of Science ®Google Scholar
• de la Motte S, Beier J, Schmid K, et al. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Ther 2012;50(6):403-12
   PubMed Web of Science ®Google Scholar
• Schmid K, Pascual S, Gil EG, et al. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, open-label, single-dose clinical trial. Clin Ther 2010;32(10):1798-812
   PubMed Web of Science ®Google Scholar
• Lasseter K, Dilzer S, Jansat JM, et al. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulm Pharmacol Ther 2012;25(2):193-9
   PubMed Web of Science ®Google Scholar
• Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci 1993;52(26):2145-60
   PubMed Web of Science ®Google Scholar
• Linden A, Rabe KF, Lofdahl CG. Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists. Lung 1996;174(1):1-22
   PubMed Web of Science ®Google Scholar
• Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164(5):778-84
   PubMed Web of Science ®Google Scholar
• Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994;7(2):103-7
   PubMedGoogle Scholar
• Cazzola M, Rogliani P, Segreti A, Matera MG. An update on bronchodilators in Phase I and II clinical trials. Expert Opin Investig Drugs 2012;21(10):1489-501
   PubMed Web of Science ®Google Scholar
• Anoro Ellipta package insert. Available from: https://wwwgsksourcecom/gskprm/htdocs/documents/ANORO-ELLIPTA-PI-MGPDF
   Google Scholar
• Sliwinski P, Perng D-W, Chuchalin A, Jones PW. Efficacy and safety of once-daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD (Abstract). Thorax 2010;65:A136
   Web of Science ®Google Scholar
• Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med 2014;14(1):178
   PubMed Web of Science ®Google Scholar
• D’Urzo A, Rennard S, Mergel V, et al. The AUGMENT COPD Trial: efficacy and safety of a fixed-dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest 2014;145(3 Suppl):426A
   Web of Science ®Google Scholar
• D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res 2014;15(1):123
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187(4):347-65
   PubMed Web of Science ®Google Scholar
• Casaburi R, Celli B, Crapo J, et al. The COPD Biomarker Qualification Consortium (CBQC). COPD 2013;10(3):367-77
   PubMedGoogle Scholar
• Pelaia G, Vatrella A, Gallelli L, et al. Biological targets for therapeutic interventions in COPD: clinical potential. Int J Chron Obstruct Pulmon Dis 2006;1(3):321-34
   PubMedGoogle Scholar